These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 17922444

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J, López-Gómez JM, Aljama P.
    Nefrologia; 2005 Nov; 25(3):297-306. PubMed ID: 16053011
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The need for better control of secondary hyperparathyroidism.
    Locatelli F.
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Hyperphosphatemia and cardiovascular risk in patients on dialysis].
    Basić-Jukić N, Kes P.
    Acta Med Croatica; 2004 Aug; 58(3):207-13. PubMed ID: 15503684
    [Abstract] [Full Text] [Related]

  • 8. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
    Martola L, Elinder CG, Stenvinkel P.
    Lakartidningen; 2003 Dec 11; 100(50):4180-3. PubMed ID: 14717005
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M, Butti A, Chiarelli G, Rocca-Rey L, Santagostino G, Gallieni M, Brancaccio D.
    Ital Heart J Suppl; 2005 Jan 11; 6(1):25-8. PubMed ID: 15776728
    [Abstract] [Full Text] [Related]

  • 12. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B, Belozeroff V.
    Eur J Clin Invest; 2007 Aug 11; 37(8):607-22. PubMed ID: 17635571
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients.
    Sit D, Kadiroglu AK, Yilmaz ME, Kara IH, Isikoglu B.
    Ren Fail; 2005 Aug 11; 27(4):403-7. PubMed ID: 16060127
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ.
    Ther Apher Dial; 2007 Oct 11; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G, Maggioni AP.
    Adv Ther; 2009 May 11; 26(5):469-87. PubMed ID: 19444394
    [Abstract] [Full Text] [Related]

  • 20. [Prevention of extraskeletal calcifications in uremia].
    Cozzolino M, Galassi A, Bellasi A, Butti A, Zoni U, Gallieni M, Brancaccio D.
    G Ital Nefrol; 2005 May 11; 22 Suppl 31():S53-5. PubMed ID: 15786403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.